Springworks Therapeutics, Inc. (SWTX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Springworks Therapeutics, Inc. (SWTX)
Go deeper and ask any question about SWTX
Company Performance
Current Price
as of Sep 17, 2024$35.42
P/E Ratio
N/A
Market Cap
$2.63B
Description
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Metrics
Overview
- HQStamford, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerSWTX
- Price$35.42-0.39%
Trading Information
- Market Cap$2.63B
- Float90.18%
- Average Daily Volume (1m)754,626
- Average Daily Volume (3m)853,865
- EPS-$4.28
Company
- Revenue$86.19M
- Rev Growth (1yr)N/A
- Net Income-$39.92M
- Gross Margin94.48%
- EBITDA Margin-73.79%
- EBITDA-$44.08M
- EV$2.42B
- EV/Revenue28.02
- P/EN/A
- P/S30.46
Documents
SEC Filings
Factset Street Account